MB12 (pembrolizumab biosimilar) / mAbxience - LARVOL DELTA

BENITO Study: A PK‑Driven Biosimilarity Study of MB12 to pembrolizumab in Advanced non-squamous non-small cell lung cancer. (ESMO 2026) - No abstract available

Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov) - P3 | N=726 | Active, not recruiting | Sponsor: mAbxience Research S.L. | Recruiting ➔ Active, not recruiting

Enrollment closed • IO biomarker • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov) - P3 | N=726 | Recruiting | Sponsor: mAbxience Research S.L. | Trial primary completion date: Jun 2026 ➔ Aug 2026

IO biomarker • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov) - P3 | N=726 | Recruiting | Sponsor: mAbxience Research S.L. | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov) - P3 | N=726 | Not yet recruiting | Sponsor: mAbxience Research S.L.

New P3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

MB12-C-01-22: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov) - P3 | N=174 | Recruiting | Sponsor: Laboratorio Elea Phoenix S.A. | Trial completion date: Dec 2025 ➔ Dec 2024 | Trial primary completion date: Aug 2025 ➔ Aug 2024

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov) - P3 | N=174 | Recruiting | Sponsor: Laboratorio Elea Phoenix S.A. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2025 ➔ Dec 2025 | Initiation date: Mar 2023 ➔ Aug 2023 | Trial primary completion date: Mar 2025 ➔ Aug 2025

Enrollment open • Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1